研究者詳細 - 金沢　賢也

論文 - 金沢　賢也

分割表示540 件中 181 - 200 件目／全件表示 >>

Clinical Outcomes of Postoperative Adjuvant Chemotherapy for Surgically Resected High-Grade Pulmonary Neuroendocrine Carcinoma.

Kotake M, Imai H, Kaira K, Endoh H, Yamada Y, Kaburagi T, Kiyoshima M, Sugiyama T, Nakamura Y, Kasai T, Matsuguma H, Minemura H, Kanazawa K, Suzuki H, Fujita A, Minato K

Chemotherapy 67 ( 3 ) 142 - 151 2022年（ ISSN:0009-3157 ）

Pretreatment glasgow prognostic score predicts survival among patients administered first-line atezolizumab plus carboplatin and etoposide for small cell lung cancer.

Wasamoto S, Imai H, Tsuda T, Nagai Y, Minemura H, Yamada Y, Umeda Y, Kishikawa T, Shiono A, Kozu Y, Shiihara J, Yamaguchi O, Mouri A, Kaira K, Kanazawa K, Taniguchi H, Kaburagi T, Minato K, Kagamu H

Frontiers in oncology 12 1080729 2022年（ ISSN:2234-943X ）

Clinical Outcomes of Postoperative Adjuvant Chemotherapy for Surgically Resected High-Grade Pulmonary Neuroendocrine Carcinoma.

Kotake M, Imai H, Kaira K, Endoh H, Yamada Y, Kaburagi T, Kiyoshima M, Sugiyama T, Nakamura Y, Kasai T, Matsuguma H, Minemura H, Kanazawa K, Suzuki H, Fujita A, Minato K

Chemotherapy 67 ( 3 ) 142 - 151 2022年（ ISSN:0009-3157 ）

Pretreatment glasgow prognostic score predicts survival among patients administered first-line atezolizumab plus carboplatin and etoposide for small cell lung cancer.

Wasamoto S, Imai H, Tsuda T, Nagai Y, Minemura H, Yamada Y, Umeda Y, Kishikawa T, Shiono A, Kozu Y, Shiihara J, Yamaguchi O, Mouri A, Kaira K, Kanazawa K, Taniguchi H, Kaburagi T, Minato K, Kagamu H

Frontiers in oncology 12 1080729 2022年（ ISSN:2234-943X ）

Clinical Outcomes of Postoperative Adjuvant Chemotherapy for Surgically Resected High-Grade Pulmonary Neuroendocrine Carcinoma.

Kotake M, Imai H, Kaira K, Endoh H, Yamada Y, Kaburagi T, Kiyoshima M, Sugiyama T, Nakamura Y, Kasai T, Matsuguma H, Minemura H, Kanazawa K, Suzuki H, Fujita A, Minato K

Chemotherapy 67 ( 3 ) 142 - 151 2022年（ ISSN:0009-3157 ）

Pretreatment glasgow prognostic score predicts survival among patients administered first-line atezolizumab plus carboplatin and etoposide for small cell lung cancer.

Wasamoto S, Imai H, Tsuda T, Nagai Y, Minemura H, Yamada Y, Umeda Y, Kishikawa T, Shiono A, Kozu Y, Shiihara J, Yamaguchi O, Mouri A, Kaira K, Kanazawa K, Taniguchi H, Kaburagi T, Minato K, Kagamu H

Frontiers in oncology 12 1080729 2022年（ ISSN:2234-943X ）

Clinical Outcomes of Postoperative Adjuvant Chemotherapy for Surgically Resected High-Grade Pulmonary Neuroendocrine Carcinoma.

Kotake M, Imai H, Kaira K, Endoh H, Yamada Y, Kaburagi T, Kiyoshima M, Sugiyama T, Nakamura Y, Kasai T, Matsuguma H, Minemura H, Kanazawa K, Suzuki H, Fujita A, Minato K

Chemotherapy 67 ( 3 ) 142 - 151 2022年（ ISSN:0009-3157 ）

Pretreatment glasgow prognostic score predicts survival among patients administered first-line atezolizumab plus carboplatin and etoposide for small cell lung cancer.

Wasamoto S, Imai H, Tsuda T, Nagai Y, Minemura H, Yamada Y, Umeda Y, Kishikawa T, Shiono A, Kozu Y, Shiihara J, Yamaguchi O, Mouri A, Kaira K, Kanazawa K, Taniguchi H, Kaburagi T, Minato K, Kagamu H

Frontiers in oncology 12 1080729 2022年（ ISSN:2234-943X ）

Clinical Outcomes of Postoperative Adjuvant Chemotherapy for Surgically Resected High-Grade Pulmonary Neuroendocrine Carcinoma.

Kotake M, Imai H, Kaira K, Endoh H, Yamada Y, Kaburagi T, Kiyoshima M, Sugiyama T, Nakamura Y, Kasai T, Matsuguma H, Minemura H, Kanazawa K, Suzuki H, Fujita A, Minato K

Chemotherapy 67 ( 3 ) 142 - 151 2022年（ ISSN:0009-3157 ）

Pretreatment glasgow prognostic score predicts survival among patients administered first-line atezolizumab plus carboplatin and etoposide for small cell lung cancer.

Wasamoto S, Imai H, Tsuda T, Nagai Y, Minemura H, Yamada Y, Umeda Y, Kishikawa T, Shiono A, Kozu Y, Shiihara J, Yamaguchi O, Mouri A, Kaira K, Kanazawa K, Taniguchi H, Kaburagi T, Minato K, Kagamu H

Frontiers in oncology 12 1080729 2022年（ ISSN:2234-943X ）

Pretreatment Glasgow prognostic score predicts survival among patients with high PD-L1 expression administered first-line pembrolizumab monotherapy for non-small cell lung cancer.

Imai H, Kishikawa T, Minemura H, Yamada Y, Ibe T, Yamaguchi O, Mouri A, Hamamoto Y, Kanazawa K, Kasai T, Kaira K, Kaburagi T, Minato K, Kobayashi K, Kagamu H